Structure-Guided Development of ClpP Agonists with Potent Therapeutic Activities against Staphylococcus aureus Infection
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02562 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Tao Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Drug Research, Centre for Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 20120…. Hauptthemen laut MEDLINE: Staphylococcus aureus, Anti-Bacterial Agents, Staphylococcal Infections, Endopeptidase Clp. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: National Key Research and Development Program of China, China Postdoctoral Science Foundation, Youth Innovation Promotion Association of the Chinese Academy of Sciences.
Abstract (Originalsprache)
Peritonitis caused by Staphylococcus aureus poses a severe threat to patients with end-stage renal failure. Treating multidrug-resistant S. aureus infections requires the use of antibiotics with diverse mechanisms of action. Caseinolytic protease P (ClpP) is a promising antibacterial target; however, selective activation of S. aureus ClpP (SaClpP) over human ClpP (HsClpP) remains challenging. We previously identified (R)-ZG197 as a selective SaClpP agonist, but its potency was suboptimal. Herein, we develop (R)-ZG197 analogs through a structure-guided approach and examine their structure-activity relationships. Notably, ZY39 demonstrates improved activation of SaClpP and superior binding affinity. Interestingly, while ZY39 facilitates the enzymatic hydrolysis of SaClpP and HsClpP in vitro, it does not target HsClpP in cellular environments. Furthermore, ZY39 effectively inhibits the growth of multidrug-resistant S. aureus strains and shows excellent therapeutic efficacy in a murine model of peritonitis. These findings highlight ZY39 as a promising SaClpP agonist for combating staphylococcal infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Drug Research, Centre for Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
- University of Chinese Academy of Sciences, Beijing 100049, China.
- School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.
- School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
- School of Life Sciences, Fudan University, Shanghai 200433, China.
- Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117, China.
ORCID-Profile: Jianhua Gan, Cai-Guang Yang
Förderung
- National Key Research and Development Program of China
- China Postdoctoral Science Foundation
- Youth Innovation Promotion Association of the Chinese Academy of Sciences
- National Natural Science Foundation of China
Zitieren
APA
Zhang, T., Wu, W., Zhao, Y., Ding, Z., Wei, B., Yang, T., Li, J., Wang, P., Lan, L., Gan, J., & Yang, C. G. (2025). Structure-Guided Development of ClpP Agonists with Potent Therapeutic Activities against Staphylococcus aureus Infection. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02562
Vancouver
Zhang T, Wu W, Zhao Y, Ding Z, Wei B, Yang T, et al. Structure-Guided Development of ClpP Agonists with Potent Therapeutic Activities against Staphylococcus aureus Infection. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02562
BibTeX
@article{Zhang2025,
author = {Zhang, Tao and Wu, Wei and Zhao, Yanling and Ding, Ziang and Wei, Bingyan and Yang, Teng and Li, Jiahui and Wang, Pengyu and Lan, Lefu and Gan, Jianhua and Yang, Cai-Guang},
title = {Structure-Guided Development of ClpP Agonists with Potent Therapeutic Activities against Staphylococcus aureus Infection},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02562}
}
EUVIMED